Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery

Cancer Research

Volumn 67, Issue 22, 2007, Pages 10959-10965

  Lee, Tong Young ^a   Lin, Chin Tarng ^a,b   Kuo, Szu Yao ^c   Chang, De Kuan ^a,c   Wu, Han Chung ^a,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LIPOSOME; PROLINE; PROTEIN SP5 52; SERINE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; PEPTIDE; PEPTIDE LIBRARY;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIOPHAGE; BLOOD VESSEL; CELL HOMING; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CANCER; MOUSE; MOUTH CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; SCID MOUSE; SURVIVAL RATE; TUMOR XENOGRAFT; UMBILICAL VEIN; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; CYTOLOGY; DISEASE MODEL; LUNG TUMOR; MOUSE MUTANT; MOUTH TUMOR; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; VASCULAR ENDOTHELIUM;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; MOUTH NEOPLASMS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE LIBRARY; PEPTIDES;

EID: 36348935200     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2233     Document Type: Article

References (50)

1. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95.
2. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2002;2:83-90.
3. Eliceiri BP, Cheresh DA. The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999;103:1227-30.
4. Pasqualini R, Koivunen E, Ruoslahti E. av Integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997;15:542-6.
5. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
6. Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 1988;15:15-31.
7. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999;51:691-743.
8. Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991;88:11460-4.
9. Vaage J, Barbera-Guillem E, Abra R, Huang A, Working P. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 1994;73:1478-84.
10. Colbern GT, Hiller A, Musterer RS, Pegg E, Henderson IC, Working P. Significant increase in antitumor potency of doxorubicin HCl by its encapsulation in pegylated liposomes. J Liposome Res 1999;9:523-38.
11. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-92.
12. Marina NM, Cochrane D, Harney E, et al. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a Pediatric Oncology Group Study. Clin Cancer Res 2002;8:413-8.
13. 2. Ann Oncol 2000;11:1029-33.
14. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997;54:15-21.
15. Dvorak HF, Nagy JA, Dvorak AM. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 1991;3:77-85.
16. Shockley TR, Lin K, Nagy JA, Tompkins RG, Dvorak HF, Yarmush ML. Penetration of tumor tissue by antibodies and other immunoproteins. Ann N Y Acad Sci 1991;618:367-82.
17. Fu Y, Shearing LN, Haynes S, et al. Isolation from phage display libraries of single chain variable fragment antibodies that recognize conformational epitopes in the malaria vaccine candidate, apical membrane antigen-1. J Biol Chem1997;272:2 5678-84.
18. Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science 1990;249:386-90.
19. Wu HC, Huang YL, Chao TT, et al. Identification of B-cell epitope of dengue virus type 1 and its application in diagnosis of patients. J Clin Microbiol 2001;39:977-82.
20. Wu HC, Jung MY, Chiu CY, et al. Identification of a dengue virus type 2 (DEN-2) serotype-specific B-cell epitope and detection of DEN-2-immunized animal serumsam ples using an epitope-based peptide antigen. J Gen Virol 2003;84:2771-9.
21. Atwell S, Ultsch M, De Vos AM, Wells JA. Structural plasticity in a remodeled protein-protein interface. Science 1997;278:1125-8.
22. Bottger V, Bottger A, Howard SF, et al. Identification of novel mdm2 binding peptides by phage display. Oncogene 1996;13:2141-7.
23. Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren PA. Binding proteins selected fromcom binatorial libraries of an α-bacterial receptor domain. Nat Biotechnol 1997;15:772-7.
24. Li B, Tom JY , Oare D, et al. Minimization of a polypeptide hormone. Science 1995;270:1657-60.
25. Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996;273:458-64.
26. Castano AR, Tangri S, Miller JE, et al. Peptide binding and presentation by mouse CD1. Science 1995;269:223-6.
27. Kraft S, Diefenbach B, Mehta R, Jonczyk A, Luckenbach GA, Goodman SL. Definition of an unexpected ligand recognition motif for αv β6 integrin. J Biol Chem19 99;274:1979-85.
28. Pasqualini R, Koivunen E, Ruoslahti E. A peptide isolated fromphage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J Cell Biol 1995;130:1189-96.
29. Folgori A, Tafi R, Meola A, et al. A general strategy to identify mimotopes of pathological antigens using only randompeptide libraries and human sera. EMBO J 1994;13:2236-43.
30. Prezzi C, Nuzzo M, Meola A, et al. Selection of antigenic and immunogenic mimics of hepatitis C virus using sera from patients. J Immunol 1996;156:4504-13.
31. Liu IJ, Hsueh PR, Lin CT, et al. Disease-specific B cell epitopes for serumantibod ies frompatien ts with severe acute respiratory syndrome (SARS) and serologic detection of SARS antibodies by epitope-based peptide antigens. J Infect Dis 2004;190:797-809.
32. Barry MA, Dower WJ, Johnston SA. Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med 1996;2:299-305.
33. Lee TY, Wu HC, Tseng YL, Lin CT. A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res 2004;64:8002-8.
34. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996;380:364-6.
35. Chu YW, Yang PC, Yang SC, et al. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 1997;17:353-60.
36. Tseng YL, Hong RL, Tao MH, Chang FH. Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int J Cancer 1999;80:723-30.
37. Habeeb AFSA. Determination of free amino groups in protein by trinitrobenzene sulfuric acid. Anal Biochem 1966;14:328.
38. Zalipsky S, Mullah N, Harding JA, Gittelman J, Guo L, DeFrees SA. Poly(ethylene glycol)-grafted liposomes with oligopeptide or oligosaccharide ligands appended to the termini of the polymer chains. Bioconjug Chem 1997;8:111-8.
39. Kirpotin D, Park JW, Hong K, et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997;36:66-75.
40. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8:1172-81.
41. Oku N, Asai T, Watanabe K, et al. Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene 2002;21:2662-9.
42. Hoffman JA, Giraudo E, Singh M, et al. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 2003;4:383-91.
43. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7.
44. Denekamp J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993;66:181-96.
45. Burrows FJ, Thorpe PE. Vascular targeting: a new approach to the therapy of solid tumors. Pharmacol Ther 1994;64:155-74.
46. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-13.
47. Less JR, Posner MC, Boucher Y, Borochovitz D, Wolmark N, Jain RK. Interstitial hypertension in human breast and colorectal tumors. Cancer Res 1992;52:6371-4.
48. Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 1991;51:6691-4.
49. Gutmann R, Leunig M, Feyh J, et al. Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res 1992;52:1993-5.
50. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990;50:4478-84.